ChromaDex (CDXC) Announces Retail Distribution of Tru Niagen in Walmart Stores Across the United States
Get Alerts CDXC Hot Sheet
Join SI Premium – FREE
ChromaDex Corp. (NASDAQ: CDXC) announced today its flagship consumer product and industry-leading NAD+ booster Tru Niagen® will be available in 3,000 Walmart retail stores across the United States beginning June 2021. ChromaDex will introduce Tru Niagen® in two packaging options for Walmart customers, which will have distinct serving sizes and price points. In addition to in-store availability, these two options will be available online with same-day delivery and in-store pickup options for select locations.
“We believe Tru Niagen® is one of the most important new dietary supplements to emerge in many years,” says ChromaDex CEO Rob Fried. “We are grateful to Walmart in assisting in our quest to help as many people as possible to Age Better®.”
Tru Niagen® helps users Age Better® by safely and effectively increasing NAD+ (nicotinamide adenine dinucleotide) supporting the trillions of cells in the body. NAD+ levels decline with age as well as physiological stressors including stress on the immune system, alcohol consumption, over-exercising, and lack of healthy sleep cycles. Niagen® (patented nicotinamide riboside) increases NAD+ levels safely and efficaciously, as demonstrated in nine published human trials. Niagen® has received regulatory acceptance by the world’s four leading regulatory bodies: the U.S. FDA, Health Canada, the European Commission, and the Therapeutic Goods Administration (TGA) of Australia. Scientifically superior to competing NAD+ precursors such as NMN (nicotinamide mononucleotide), Niagen® is supported by a vast amount of safety and efficacy data in humans.
For additional information on the science supporting Tru Niagen®, please visit www.truniagen.com.
For additional information about ChromaDex, please visit www.chromadex.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MacroGenics to receive $24.5M milestone from Sanofi on FDA approval
- Palantir selected as cloud data layer for U.S. Army NGC2 program
- NVE Corp CEO to retire, successor named for August transition
Create E-mail Alert Related Categories
Corporate News, Hot Corp. News, Management CommentsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share